Received May 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
The patient received the 2nd dose of twinrix after 6 months instead of after 1 month; This non-serious case was reported by a pharmacist via sales rep and described the occurrence of drug dose administration interval too long in a 54-year-old female patient who received HAB (Twinrix) for prophylaxis. Previously administered products included Twinrix (received 1st dose (Left arm) on 03-MAY-2024 with batch number: 429jj and expiry date: 01-APR-2026). On an unknown date, the patient received the 2nd dose of Twinrix. On an unknown date, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: The patient received the 2nd dose of twinrix after 6 months instead of after 1 month). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 02-MAY-2025 The pharmacist reported that the patient received the 2nd dose of Twinrix after 6 months instead of after 1 month. The patient received 2nd dose of Twinrix, later than the recommended interval, which led to lengthening of vaccination schedule.